Enterprise Value
479.7M
Cash
526.4M
Avg Qtr Burn
-15.16M
Short % of Float
6.79%
Insider Ownership
6.17%
Institutional Own.
91.75%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BT5528 (EphA2) Details Solid tumor/s | Phase 1/2 Data readout | |
BT8009 (Nectin-4) Details Solid tumor/s, Cancer, Urothelial cancer, Bladder cancer | Phase 1/2 Data readout | |
BT1718 (MT1-MMP) Details Non-small cell lung carcinoma, Solid tumor/s, Cancer | Phase 1/2 Update | |
BT7480 (Nectin-4 CD137, TICA) Details Solid tumor/s, Cancer | Phase 1/2 Update |